Janux Therapeutics (JANX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Janux Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $1.1M of JANX stock on the open market.
Get emailed when insiders cluster-buy stocks like JANX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
JANX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $86K | 2 |
| Q1 2026 | — | 0 | $261K | 6 |
| Q4 2025 | — | 0 | $711K | 4 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Janux Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $1.1M. 4 of 12 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 4SEC | Janeen Noel DoyleChief Corp. & Bus. Dev. Ofcr | Sell | 4,05975,941 held (−5%) | $14.03 | $57K | +31.1% | — |
| May 13SEC | Maria DobekPresident | Sell | 2,03832,270 held (−6%) | $14.17 | $29K | +29.8% | — |
| Jan 2SEC | David Alan CampbellCEO, President | Sell | 8,072284,982 held (−3%) | $13.73 | $111K | +33.9% | — |
| Jan 2SEC | Zachariah MciverChief Medical Officer | Sell | 2,71423,286 held (−10%) | $13.73 | $37K | +33.9% | — |
| Jan 2SEC | Thomas DiraimondoChief Scientific Officer | Sell | 2,505124,425 held (−2%) | $13.73 | $34K | +33.9% | — |
| Jan 2SEC | Charles M. WinterChief Technical Officer | Sell | 2,40177,721 held (−3%) | $13.73 | $33K | +33.9% | — |
| Jan 2SEC | Andrew Hollman MeyerChief Business Officer | Sell | 1,87983,095 held (−2%) | $13.73 | $26K | +33.9% | — |
| Jan 2SEC | Maria DobekPresident | Sell | 1,46215,373 held (−9%) | $13.73 | $20K | +33.9% | — |
| Dec 3SEC | Andrew Hollman MeyerChief Business Officer | Sell Plan | 2,70085,607 held (−3%) | $32.85 | $89K | -44.0% | — |
| Dec 3SEC | Andrew Hollman MeyerChief Business Officer | Sell Plan | 63384,974 held (−1%) | $33.52 | $21K | -45.1% | — |
| Nov 14SEC | Andrew Hollman MeyerChief Business Officer | Sell Plan | 3,33384,974 held (−4%) | $30.00 | $100K | -38.7% | — |
| Oct 30SEC | Andrew Hollman MeyerChief Business Officer | Sell Plan | 16,66582,139 held (−17%) | $30.06 | $501K | -38.8% | — |
Insiders at Janux Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Andrew Hollman MeyerChief Business Officer | — | $737K | Jan 2, 2026 | — |
| David Alan CampbellCEO, President | — | $111K | Jan 2, 2026 | — |
| Janeen Noel DoyleChief Corp. & Bus. Dev. Ofcr | — | $57K | Jun 4, 2026 | — |
| Maria DobekPresident | — | $49K | May 13, 2026 | — |
| Zachariah MciverChief Medical Officer | — | $37K | Jan 2, 2026 | — |
| Thomas DiraimondoChief Scientific Officer | — | $34K | Jan 2, 2026 | — |
| Charles M. WinterChief Technical Officer | — | $33K | Jan 2, 2026 | — |
JANX stock: common questions
Are Janux Therapeutics, Inc. insiders buying JANX stock?
In the past 12 months, 0 insiders reported open-market purchases of JANX worth $0.
Are Janux Therapeutics, Inc. insiders selling JANX stock?
7 insiders reported sales worth $1.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is JANX's 52-week range?
Over the past year JANX has traded between $12.18 and $34.74. It last closed at $18.39 on Oct 9, 2026.